ORLANDO, FL — February 26, 2002 — Data presented today at the 15th annual meeting of the American Association for Geriatric Psychiatry (AAGP) suggest that treatment with the cholinesterase inhibitor Exelon® (rivastigmine tartrate) may improve activities of daily living (ADLs) in patients with Alzheimer's disease across all stages assessed (mild, moderate, and moderately severe).
Researchers looked at results from the three pivotal double-blind, placebo-controlled trials of 2,105 people with Alzheimer's disease. The data were pooled and at 26 weeks patients receiving 6-12 mg/day rivastigmine demonstrated statistically significant improvements when compared to placebo-treated patients in measurements of ADLs, such as the ability to use the telephone or dress themselves, across mild, moderate, and moderately severe disease stages. Exelon is indicated for the treatment of mild-to-moderate Alzheimer's disease.
"It's important that we measure the impact of Alzheimer's disease treatment on Activities of Daily Living because that's a good gauge of how Alzheimer's disease adversely affects how people function in practical, real-world settings, and because it is of great concern to patients and their families," said Steven G. Potkin, MD, a psychiatrist from the University of California, Irvine and the study's lead author. "In the study, patients who were treated with rivastigmine consistently showed benefits on activities that were assessed compared to those receiving placebo." …
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!